Risk Factors Influencing Complications of Cardiac Implantable Electronic Device Implantation: Infection, Pneumothorax and Heart Perforation

A Nationwide Population-Based Cohort Study

Yu-Sheng Lin, MD, Sheng-Ping Hung, Pei-Rung Chen, Chia-Hung Yang, MD, Hung-Ta Wo, MD, Po-Cheng Chang, MD, Chun-Chieh Wang, MD, Chung-Chuan Chou, MD, Ming-Shien Wen, MD, Chang-Ming Chung, MD, and Tien-Hsing Chen, MD

Abstract: As the number of cardiac implantable electronic devices (CIEDs) is increasing annually, CIED-related complications are becoming increasingly important. The aim of the study was to assess the risks associated with CIEDs by a nationwide database.

Patients were selected from the Taiwan National Health Insurance Database. Admissions for CIED implantation, replacement, and revision were evaluated and the evaluation period was 14 years. Endpoints included CIED-related infection, pneumothorax, and heart perforation.

The study included 40,608 patients with a mean age of 71.8 ± 13.3 years. Regarding infection, the incidence rate was 2.45 per 1000 CIED-years. Male gender, younger age, device replacement, and previous infection were risks for infection while old age and high-volume centers (>200 per year) were protectors. The incidence of pneumothorax was 0.6%, with an increased risk in individuals who had chronic obstructive lung disease (COPD) and cardiac resynchronized therapy (CRT). The incidence of heart perforation was 0.009%, with an increased risk in individuals who had pre-operation temporal pacing and steroid use.

High-volume center was found to decrease infection rate while male gender, young people, and individuals who underwent replacements were associated with an increased risk of infection. Additionally, pre-operation temporal pacing and steroid use should be avoided if possible. Furthermore, COPD patients or those who accept CRTs should be monitored closely.

(Medicine 93(27):c213)

INTRODUCTION

Cardiovascular implantable electronic devices (CIEDs), which include pacemakers (PM), implantable cardioverter-defibrillators (ICD), and cardiac resynchronized therapy (CRT), are standard therapy for bradyarrhythmias, tachyarrhythmias, and systolic heart failure with left bundle branch block. Though the numbers of these devices have increased annually over the last decade, as the population with implanted devices continues to grow, CIED-related complications such as infection, pneumothorax and cardiac perforation have increased as well. Such complications not only result in prolonged hospitalization and increased costs, but also worse outcomes and mortality. For this reason, many studies have attempted to investigate the factors causing CIED-related complications by evaluating baseline characteristics, procedure types, and medications.

Among the device-related complications, infection has attracted most of our attention. Some studies have reported some factors contributing to infection, such as diabetes mellitus (DM), end-stage renal disease (ESRD), corticosteroid use, early re-intervention, temporary pacing, as well as physician experience in CIED implantation and revision/replacement procedures. However, the conclusions have been inconsistent. Baddour et al pointed out that these studies had various limitations such as relatively small numbers of CIED infection patients, and individual single-center.

In addition to CIED-related infection, evaluating the risks of other complications such as pneumothorax and heart perforation is also important. Pneumothorax after implantation has supposedly shown a correlation with subclavian vein puncture, old age, female gender, and operator experience, causing increased patient morbidity and substantial cost. Another associated complication is heart perforation, though relatively rare with an incidence reported from between 0.09% to 1.2% in the medical literature. Some studies have pointed out certain risk factors for heart perforation such as temporary pacemakers, steroid use within 7 days prior to implantation, and helical screws. However, compared to studies of device-related CIED...
infections, there has been little research assessing the risk of pneumothorax and heart perforation in CIED patients.

In order to fill this lacuna in the literature and evaluate CIED-related complications in Asian populations, a nationwide database was analyzed to identify possible risk factors and incidences of CIED-related complications.

MATERIALS AND METHODS

Data Source and Design of outcomes

This retrospective national population-based cohort study was retrieved from the National Health Insurance Research Database (NHIRD) released by the Taiwan National Health Research Institute. The NHIRD enrolls 99.91% of the Taiwanese population (about 23.20 million in 2012) and consists of all enrollees health care data. Previous studies have described it in detail\(^\text{21}\) and validated the accuracy of the NHIRD diagnostic data.\(^\text{22}\) The insurance reimburses all the CIED implantation, replacement, revision, and removal expenses with appropriate indication according to the clinical practice guidelines of CIEDs from 1996 to the present. All CIED procedures were enrolled including new implantation, replacement due to any cause, revisions or removal procedures, but procedures that could not be clearly defined were excluded. The CIEDs include pacemakers, ICD, and CRT. The study period was between January 1, 1997 and December 31, 2010. We inspected all admissions after CIED procedures to evaluate any CIED-related complications. The end points included device-related infection, pneumothorax, and heart perforation. The cohort was followed up until either death or December 31, 2010. The ethical approval is not necessary (approved by The Institutional Review Board of Chang Gung Memorial Hospital) because the data from NHIRD was consists of deidentified secondary data and used for research purposes only.

Definitions

The cohort was divided into 3 main groups based on the outcomes: CIED infection, CIED pneumothorax, and CIED heart perforation. The CIED infection was defined as an infection that occurred during admission for CIED-related procedures, which included implantation, replacement, revision, and removal. CIED pneumothorax was defined as a pneumothorax that occurred during admission for any CIED-related procedure. CIED heart perforation was defined as a heart perforation treated with heart repair surgery during admission for any CIED-related procedure.

Risk Factor Assessment

The analyzed risk factor parameters were separated into 4 components, including patient, device, medication, and provider factors. Patient factors included gender, age, and comorbidities, which was identified based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) (as listed in Table 1). Device factors referred to CIED and procedure types. Medication factors referred to the usage of antibiotics, steroid, antiplatelets, and warfarin. Finally, the hospital procedure volume and hospital level were defined as provider factors. The hospital procedure volume was a time-dependent variable and was indicative of the annual hospital CIED procedure numbers.

Statistics

Our study noted the possibility that 1 subject might suffer 1 or more infections related to CIED procedures and replacements during the study period. Hence, independent replacement risk factors due to CIED infection were identified using multiple-event per subject Cox proportional hazard analyses. This model allowed for evaluation of time-dependent prognostic factors and multiple events. The associated complications (pneumothorax and heart repair) were identified by multivariate logistic regression analyses. The results were presented as an odds ratio (OR) for logistic regression or hazard ratio (HR) for Cox regression with corresponding 95% confidence intervals (CIs). All data analyses were conducted using SPSS software version 15.0 (SPSS Inc., Chicago, IL).

RESULTS

From January 1, 1997 to December 31, 2010, this study included 46,506 CIED procedures, which comprised of 40,608

| Variable          | Number | Percentage |
|-------------------|--------|------------|
| Gender            |        |            |
| Male              | 20,847 | 51.3%      |
| Female            | 19,761 | 48.7%      |
| Age, year (mean: 71.8, SD = 13.3) |        |            |
| <20 years         | 414    | 1.0%       |
| 20–49 years       | 1923   | 4.7%       |
| 50–59 years       | 3104   | 7.6%       |
| 60–69 years       | 7754   | 19.1%      |
| 70–79 years       | 16,051 | 39.5%      |
| >80 years         | 11,363 | 28.0%      |
| Device type       |        |            |
| Single chamber PPM| 26,443 | 65.1%      |
| Double chamber PPM| 12,059 | 29.7%      |
| ICD               | 1473   | 3.6%       |
| CRTD              | 614    | 1.5%       |
| CRTD              | 19     | 0.05%      |
| Indication        |        |            |
| AV block          | 13,802 | 34.0%      |
| Congenital AV block| 96    | 0.2%       |
| AF                | 7716   | 19.0%      |
| Sick sinus syndrome| 18,807 | 46.3%      |
| Paroxysmal ventricular tachycardia | 1520 | 3.7%   |
| Ventricular fibrillation | 416 | 1.0%   |
| Ventricular flutter | 53    | 0.1%       |
| Other left bundle branch block | 361 | 0.9%   |
| Comorbidities     |        |            |
| Diabetes          | 11,244 | 27.7%      |
| Liver cirrhosis   | 1013   | 2.5%       |
| Obstructive lung disease | 3467 | 8.5% |
| Malignant neoplasm| 3193   | 7.9%       |
| ESRD              | 3617   | 8.9%       |
| Heart failure     | 5924   | 14.6%      |
| Antibiotics       |        |            |
| Cephalosporin     | 37,723 | 92.9%      |
| Aminoglycoside    | 19,335 | 47.0%      |
| Other antibiotics | 11,359 | 28.0%      |
| Medication        |        |            |
| Antiplatelet      | 17,190 | 42.3%      |
| Warfarin          | 3160   | 7.8%       |
| Steroid           | 4811   | 11.8%      |

AF = atrial fibrillation, CRTD = cardiac resynchronized therapy-defibrillator, CRTP = cardiac resynchronized therapy-pacing, ICD = implantable cardioverter defibrillator, PPM = permanent pacemaker.
Risk Factors Associated With Infection

Several CIED infection risks were found (shown in Table 2). There were no significant differences in patient factors, except for gender and age; male patients had higher incidence of infection than females \( (P < 0.001; \text{HR: 1.68, 95\% CI: 1.37–2.05}) \); Relative to middle age (20–49 y/o), young age \( (<20\text{ y/o}; P = 0.027; \text{HR: 1.84, 95\% CI: 1.02–3.32}) \) was a risk for infection, while old age (all staged aged period >60 y/o; all \( P < 0.01; \text{HR: around 0.53–0.59}) \) prevented patients from CIED-related infection. In addition, patients with a greater frequency of previous CIED infections had a higher incidence of CIED infection. Regarding device factors, replacement procedures \( (P < 0.001; \text{HR: 1.71, 95\% CI: 1.37–2.14}) \) were an increased risk for CIED infection when compared to new implantation; dual chamber PM was a protector for CIED infection when compared to single chamber PM \( (P = 0.021; \text{HR: 0.79, 95\% CI: 0.62–1.01}) \). Among provider and medication factors, high center volume \( (>200 \text{ vs} \leq 50; P = 0.002; \text{HR: 0.54, 95\% CI: 0.36–0.80}) \) was a protector from infection; cephalosporin also trended toward preventing devices from infection \( (P = 0.078; \text{HR: 0.74, 95\% CI: 0.54–1.03}) \).

Risk Factors Associated With Complications—
Pneumothorax and Heart Perforation

The CIED pneumothorax incidence was 0.60% \((279/46,506)\) and CIED heart perforation incidence was 0.09% \((43/46,506)\) in this study. Regarding CIED pneumothorax, chronic obstructive lung disease (COPD) \( (P = 0.025; \text{HR: 1.52, 95\% CI: 1.05–2.18}) \) was a risk while DM \( (P < 0.001; \text{HR: 0.56, 95\% CI: 0.40–0.77}) \) and chronic kidney disease (CKD) \( (P = 0.034; \text{HR: 0.54, 95\% CI: 0.31–0.96}) \) might be protectors (see the left panel in Table 3). The CIED pneumothorax incidence was lower in patients accepting CIED replacement than those accepting new devices \( (P = 0.012; \text{OR: 0.66 CI: 0.48–0.91}) \); the incidence was also lower in patients accepting pacemakers than those accepting resynchronized therapy-pacing/cardiac resynchronized therapy-defibrillator \((\text{CRT-P/CRT-D}) (P = 0.02; \text{OR: 3.15 CI: 1.54–6.41})\). Regarding CIED heart perforation, there were only 2 risks identified under logistic regression analyses. One was the pre-operation temporal pacing system \( (P = 0.013; \text{OR: 2.20 CI: 1.18–4.09}) \) and the other was steroid use \( (P = < 0.001; \text{OR: 9.85 CI: 5.07–19.14}) \), as seen in the right panel of Table 3.

DISCUSSION

In this nationwide cohort study, some risk factors of the 3 catastrophes (CIED related infection, pneumothorax, and cardiac rupture) were found. Male gender, young age, CIED replacement, and previous CIED-related infection were contributors of CIED infection while old age and high-volume center were protectors. In individuals with pneumothorax, the incidence was higher in COPD patients than those without COPD, as well as the incidence was higher in patients who accepted CRT-P/CRT-D than those who accepted single chamber PM. A pre-operation temporal pacing and steroid use increased the risk of heart perforation.

Factors Contributing to Infection

The incidence of CIED infection has been evaluated since the early 1970s and has varied widely between 0.13% and 19.9%. Gould et al\(^2\) reported that a study demonstrated increasing infection rates year by year. Baddour et al\(^1\) also observed that the numbers of CIED infection-related hospitalizations increased out of proportion to rates of new device implantation. Although these conditions were not evident in our study, which showed constant infection rates per year (the incidence was 2.45/1000 CIED-years). The time to the revision/replacement (incidence 3.08/1000 PPM-years). The implantation (incidence 2.19/1000 CIED-years), 120 after years. A total of 417 CIED-related procedures due to infection requiring surgical correction. The total follow-up was 170,299 device-years; mean follow-up for each subject was 4.19 person-years. During the same CIED procedure admission, there were were 279 episodes of pneumothorax and 43 episodes of heart perforation when compared to single chamber PM. Among provider and medication factors, high center volume >200 vs ≤50, HR: 0.54, 95% CI: 0.36–0.80 was a protector from infection; cephalosporin also trended toward preventing devices from infection.
### TABLE 2. Associated Factors Related to CIED Infection

| Variable | Devices | Device-Years | Event | HR (95% CI) | P-Value | Adjusted HR (95% CI) | P-Value |
|----------|---------|--------------|-------|-------------|---------|----------------------|---------|
| **Patient factor** | | | | | | | |
| **Gender** | | | | | | | |
| Male | 23,906 | 86,191 | 263 | 1.66 (1.36–2.02) | <0.001 | 1.68 (1.37–2.05) | <0.001 |
| Female | 22,600 | 84,108 | 154 | 1 | 1 | 1 | 1 |
| **Age** | | | | | | | |
| <20 years | 639 | 2452 | 17 | 1.92 (1.08–3.42) | 0.027 | 1.84 (1.02–3.22) | 0.043 |
| 20–49 years | 2313 | 9977 | 36 | 1 | 1 | 1 | 1 |
| 50–59 years | 3593 | 14,843 | 60 | 1.10 (0.73–1.66) | 0.656 | 1.16 (0.77–1.76) | 0.482 |
| 60–69 years | 8708 | 38,114 | 74 | 0.53 (0.36–0.79) | 0.002 | 0.58 (0.38–0.86) | 0.008 |
| 70–79 years | 18,060 | 69,523 | 145 | 0.56 (0.39–0.81) | 0.002 | 0.59 (0.41–0.87) | 0.007 |
| >80 years | 13,193 | 35,390 | 85 | 0.59 (0.40–0.87) | 0.008 | 0.60 (0.40–0.90) | 0.013 |
| **Diabetes** | | | | | | | |
| No | 33,762 | 132,547 | 330 | 1 | 1 | 1 | 1 |
| Yes | 12,744 | 37,752 | 87 | 0.86 (0.68–1.10) | 0.230 | 0.91 (0.71–1.17) | 0.467 |
| **Liver cirrhosis** | | | | | | | |
| No | 45,353 | 167,608 | 410 | 1 | 1 | 1 | 1 |
| Yes | 1153 | 2691 | 7 | 0.93 (0.44–1.97) | 0.853 | 0.84 (0.39–1.78) | 0.644 |
| **Obstructive lung disease** | | | | | | | |
| No | 42,464 | 159,300 | 388 | 1 | 1 | 1 | 1 |
| Yes | 4042 | 10,999 | 29 | 1.01 (0.69–1.47) | 0.972 | 0.93 (0.63–1.37) | 0.698 |
| **CKD** | | | | | | | |
| No | 39,682 | 153,368 | 363 | 1 | 1 | 1 | 1 |
| Yes | 6824 | 16,931 | 54 | 1.21 (0.91–1.62) | 0.190 | 1.19 (0.88–1.61) | 0.257 |
| **Heart failure** | | | | | | | |
| No | 39,670 | 153,666 | 363 | 1 | 1 | 1 | 1 |
| Yes | 6824 | 16,931 | 54 | 1.21 (0.91–1.62) | 0.190 | 1.19 (0.88–1.61) | 0.257 |
| **Malignant neoplasm** | | | | | | | |
| No | 42,770 | 160,742 | 391 | 1 | 1 | 1 | 1 |
| Yes | 3736 | 9557 | 26 | 1.01 (0.68–1.51) | 0.942 | 1.03 (0.69–1.54) | 0.897 |
| **Previous infection** | | | | | | | |
| No | 39,776 | 152,722 | 338 | 1 | 1 | 1 | 1 |
| 1 time | 4972 | 13,958 | 46 | 1.40 (1.03–1.91) | 0.031 | 1.32 (0.96–1.81) | 0.085 |
| 2 times | 1159 | 2445 | 19 | 3.09 (1.94–4.91) | <0.001 | 2.86 (1.77–4.61) | <0.001 |
| More than 3 times | 599 | 1174 | 14 | 4.73 (2.77–8.07) | <0.001 | 3.79 (2.16–6.64) | <0.001 |
| **Device factors** | | | | | | | |
| **Type of procedure** | | | | | | | |
| New implant | 35,308 | 132,617 | 290 | 1 | 1 | 1 | 1 |
| Replacement | 10,731 | 35,406 | 120 | 1.71 (1.37–2.14) | <0.001 | 1.97 (1.54–2.52) | <0.001 |
| Revision or removal | 467 | 2276 | 7 | 1.52 (0.72–3.21) | 0.277 | 1.13 (0.52–2.42) | 0.760 |
| **Device type** | | | | | | | |
| Single chamber PPM | 29,344 | 127,632 | 317 | 1 | 1 | 1 | 1 |
| Double chamber PPM | 14,494 | 36,712 | 82 | 0.79 (0.62–1.01) | 0.062 | 0.71 (0.53–0.94) | 0.017 |
| ICD | 1839 | 4212 | 15 | 1.27 (0.75–2.13) | 0.369 | 1.01 (0.58–1.77) | 0.965 |
| CRT/P/CRTD | 829 | 1744 | 3 | 0.61 (0.19–1.89) | 0.388 | 0.53 (0.16–1.70) | 0.283 |
| **Temporal PPM** | | | | | | | |
| No | 32,041 | 114,374 | 267 | 1 | 1 | 1 | 1 |
| Yes | 14,465 | 55,925 | 150 | 1.16 (0.95–1.42) | 0.140 | 1.19 (0.97–1.47) | 0.095 |
| **Provider factors** | | | | | | | |
| **Year of procedure** | | | | | | | |
| 1997–2000 | 8233 | 50,189 | 127 | 1 | 1 | 1 | 1 |
| 2001–2005 | 15,217 | 75,329 | 155 | 0.83 (0.65–1.05) | 0.118 | 0.80 (0.62–1.03) | 0.078 |
| 2006–2010 | 23,056 | 44,781 | 135 | 0.93 (0.72–1.19) | 0.549 | 0.92 (0.68–1.24) | 0.591 |
| **Center volume (quartile)** | | | | | | | |
| ≤50 | 12,055 | 43,585 | 128 | 1 | 1 | 1 | 1 |
| 51–100 | 11,598 | 45,597 | 108 | 0.82 (0.64–1.06) | 0.137 | 0.78 (0.57–1.06) | 0.108 |
| 101–200 | 12,274 | 45,061 | 113 | 0.86 (0.66–1.10) | 0.226 | 0.79 (0.56–1.10) | 0.164 |
| >200 | 10,579 | 36,056 | 68 | 0.64 (0.47–0.86) | 0.003 | 0.54 (0.36–0.80) | 0.002 |
been proposed explaining the increased pediatric infection risk, including more abdominal approaches in children and a greater frequency of replacement, no studies have decidedly verified any hypothesis. In our study, we found CIED replacement is an independent risk for infection and more epicardial leads and higher prevalence of replacement were noted in younger-aged participants than older-aged ones (Supplementary, http://links.lww.com/MD/A85, and http://links.lww.com/MD/A86). This study can thus indirectly confirm 1 hypothesis. As for provider factors, high risk of ICD infection associated with lower physician volume was reported by Al-Khatib et al24 but high hospital volume was proven to decrease the risk of ICD implantation complications in a retrospective study.25 Unfortunately, no previous study could establish an effect of hospital volume in other CIEDs.11,14 In this study, we showed that hospital volume had a significant effect on overall CIED-related infection. When combining the Danish registry data11 and ours, both hospital volume and operator experience were important factors in CIED-related infection control.

Factors Contributing to Pneumothorax

The incidence of CIED related pneumothorax was reported as 1.7% in a single center30 and was 0.60% over a 14-year observation period in a national registry.17 In this study, our result (0.60% (279/46,506)) was comparable to presented incidence in the literature. Regarding of risks for pneumothorax, the Danish registry showed that COPD and dual chamber device were important risks for pneumothorax and they also supposed CRT may be a risk. In our study, CRT-P/D was proven as a risk of pneumothorax. Similarly, our study also was able to confirm the hypothesis that replacement is a protector (given the absence of lead insertions). Other protective factors for pneumothorax were diabetes and CKD, but no evidence has emerged to show why the above variables became predictors. A possible explanation is that the previously mentioned comorbidities are notorious risks for cardiovascular disease, making cardiologists pay greater attention to patients undergoing procedures with these comorbidities.

Factors Contributing to Heart Perforation

Heart perforation has been a rare but significant complication after CIED implantation. Khan et al31 summarized event rates ranging from 0.1% to 0.8% for pacemakers and 0.6–5.2% infection published in the literature, such as DM, heart failure,9,27,28 corticosteroid13 and anticoagulation,29 did not achieve statistical significance but they nonetheless did correspond to another large prospective multicenter study.14

| Variable                       | Devices | Device-Years | Event | HR (95% CI) | P-Value | Adjusted HR (95% CI) | P-Value |
|--------------------------------|---------|--------------|-------|-------------|---------|----------------------|---------|
| Hospital level                 |         |              |       |             |         |                      |         |
| Medical center                 | 28,942  | 109,023      | 253   | 1           | 1       |                      |         |
| Metropolitan                   | 16,427  | 58,108       | 151   | 1.10 (0.90–1.34) | 0.374   | 0.95 (0.71–1.25)     | 0.702   |
| Local community                | 1137    | 3168         | 13    | 1.64 (0.94–2.87) | 0.081   | 1.35 (0.72–2.50)     | 0.346   |
| Medication factors             |         |              |       |             |         |                      |         |
| Antibiotics                    |         |              |       |             |         |                      |         |
| Cephalosporin                  |         |              |       |             |         |                      |         |
| No                             | 3353    | 11,083       | 45    | 1           | 1       |                      |         |
| Yes                            | 43,153  | 159,216      | 372   | 0.59 (0.43–0.80) | 0.001   | 0.74 (0.54–1.03)     | 0.078   |
| Aminoglycoside                 |         |              |       |             |         |                      |         |
| No                             | 24,735  | 81,183       | 213   | 1           | 1       |                      |         |
| Yes                            | 21,771  | 89,116       | 204   | 0.92 (0.75–1.11) | 0.366   | 0.88 (0.72–1.08)     | 0.229   |
| Other antibiotics              |         |              |       |             |         |                      |         |
| No                             | 33,671  | 129,561      | 291   | 1           | 1       |                      |         |
| Yes                            | 12,835  | 40,738       | 126   | 1.32 (1.07–1.63) | 0.009   | 1.16 (0.92–1.46)     | 0.209   |
| Steroid                        |         |              |       |             |         |                      |         |
| No                             | 41,301  | 156,358      | 374   | 1           | 1       |                      |         |
| Yes                            | 5205    | 13,941       | 43    | 1.19 (0.86–1.63) | 0.289   | 0.92 (0.66–1.29)     | 0.632   |
| Warfarin or Anti platelet      |         |              |       |             |         |                      |         |
| No use                         | 25,396  | 95,696       | 237   | 1           | 1       |                      |         |
| Antiplatelet only              | 17,525  | 61,987       | 140   | 0.90 (0.73–1.11) | 0.309   | 0.96 (0.77–1.19)     | 0.678   |
| Warfarin only                  | 2347    | 8434         | 24    | 1.14 (0.75–1.73) | 0.547   | 0.98 (0.64–1.52)     | 0.937   |
| Both                           | 1238    | 4182         | 16    | 1.51 (0.91–2.50) | 0.112   | 1.45 (0.86–2.43)     | 0.161   |

AF = atrial fibrillation, AHR = adjusted hazard ratio, CIED = cardiac implantable electronic device, CKD = chronic kidney disease, CRTD = cardiac resynchronized therapy-defibrillator, CRTP = cardiac resynchronized therapy-pacing, ICD = implantable cardioverter defibrillator, PPM = permanent pacemaker.
for ICD. In our study, the event rate for heart perforation was lower than rates reported in literature at 0.09%, though the major reason may be our restricted definition focusing on the complications requiring intervention. In addition, some studies have mentioned that heart perforation incidence may be underestimated due to the fact that many perforations lack clinical symptoms. Regarding the risk of heart perforation, a cohort study from the Mayo clinic noted 2 strong predictors: temporary transvenous pacemaker installation and steroid use. These 2 risks were proven again in our study.

TABLE 3. Associated CIED-Related Complication Factors: CIED Pneumothorax and CIED Heart Perforation

| Variable                      | CIED Pneumothorax                  | CIED Heart Perforation                  |
|-------------------------------|------------------------------------|----------------------------------------|
|                               | AOR (95% CI)                       | P-Value                                | AOR (95% CI)                       | P-Value                                |
| Patient factors               |                                    |                                        |                                        |                                        |
| Gender, male                  | 1.07 (0.84–1.36)                   | 0.566                                  | 0.59 (0.31–1.10)                   | 0.097                                  |
| Age                           |                                    |                                        |                                        |                                        |
| <20 years                     | 0.71 (0.24–2.11)                   | 0.542                                  | 3.45 (0.70–16.89)                  | 0.127                                  |
| 20–49 years                   | 1                                  |                                        | 1                                    |                                        |
| 50–59 years                   | 0.60 (0.32–1.14)                   | 0.118                                  | 0.59 (0.12–2.98)                   | 0.521                                  |
| 60–69 years                   | 0.53 (0.30–0.92)                   | 0.024                                  | 0.81 (0.21–3.13)                   | 0.758                                  |
| 70–79 years                   | 0.69 (0.42–1.12)                   | 0.135                                  | 0.41 (0.10–1.60)                   | 0.199                                  |
| >80 years                     | 0.91 (0.55–1.49)                   | 0.699                                  | 0.90 (0.24–3.34)                   | 0.870                                  |
| Diabetes                      | 0.56 (0.40–0.77)                   | <0.001                                 | 1.23 (0.61–2.48)                   | 0.568                                  |
| Liver cirrhosis               | 0.96 (0.42–2.19)                   | 0.927                                  | 0.97 (0.13–7.27)                   | 0.977                                  |
| Obstructive lung disease      | 1.52 (1.05–2.18)                   | 0.025                                  | 0.34 (0.08–1.43)                   | 0.141                                  |
| Malignant neoplasm            | 1.00 (0.65–1.54)                   | 0.999                                  | 0.58 (0.14–2.43)                   | 0.453                                  |
| CKD                           | 0.54 (0.31–0.96)                   | 0.034                                  | 0.76 (0.26–2.22)                   | 0.611                                  |
| Heart failure                 | 0.82 (0.56–1.20)                   | 0.309                                  | 0.73 (0.32–1.70)                   | 0.471                                  |
| Device factors                |                                    |                                        |                                        |                                        |
| Type of procedure             |                                    |                                        |                                        |                                        |
| New implant                   | 1                                  |                                        | 1.75 (0.81–3.76)                   | 0.152                                  |
| Replacement                   | 0.66 (0.48–0.91)                   | 0.012                                  | 2.32 (0.52–10.36)                  | 0.270                                  |
| Revision or removal           | 0.30 (0.04–2.19)                   | 0.237                                  |                                        |                                        |
| Device type                   |                                    |                                        |                                        |                                        |
| Single chamber PPM            | 1                                  |                                        |                                        |                                        |
| Double chamber PPM            | 1.29 (0.95–1.74)                   | 0.106                                  | 0.41 (0.16–1.06)                   | 0.065                                  |
| ICD                           | 1.55 (0.84–2.84)                   | 0.160                                  | NA                                   | NA                                     |
| CRTP/CRTD                     | 3.15 (1.54–6.41)                   | 0.002                                  | 3.74 (0.74–18.89)                  | 0.110                                  |
| Temporal PPM                  | 0.87 (0.67–1.15)                   | 0.331                                  | 2.20 (1.18–4.09)                   | 0.013                                  |
| Provider factors              |                                    |                                        |                                        |                                        |
| Year of procedure             |                                    |                                        |                                        |                                        |
| 1997–2000                     | 1                                  |                                        | 1                                    |                                        |
| 2001–2005                     | 0.76 (0.53–1.10)                   | 0.146                                  | 1.78 (0.73–4.30)                   | 0.204                                  |
| 2006–2010                     | 0.91 (0.62–1.33)                   | 0.618                                  | 1.21 (0.43–3.23)                   | 0.706                                  |
| Center volume (quartile)      |                                    |                                        |                                        |                                        |
| ≤50                           | 1                                  |                                        | 1                                    |                                        |
| 51–100                        | 1.07 (0.74–1.55)                   | 0.718                                  | 0.86 (0.34–2.15)                   | 0.740                                  |
| 101–200                       | 1.13 (0.74–1.72)                   | 0.570                                  | 1.23 (0.48–3.17)                   | 0.665                                  |
| >200                          | 0.94 (0.59–1.51)                   | 0.810                                  | 0.58 (0.16–2.05)                   | 0.397                                  |
| Hospital level                |                                    |                                        |                                        |                                        |
| Medical center                | 1                                  |                                        | 1                                    |                                        |
| Metropolitan                  | 1.14 (0.81–1.60)                   | 0.450                                  | 1.64 (0.74–3.66)                   | 0.227                                  |
| Local community               | 1.34 (0.63–2.83)                   | 0.445                                  | 1.66 (0.19–14.51)                  | 0.645                                  |
| Medication factors            |                                    |                                        |                                        |                                        |
| Steroid                       | 1.38 (0.97–1.97)                   | 0.072                                  | 9.85 (5.07–19.14)                  | <0.001                                  |
| Warfarin or antiplatelets     |                                    |                                        |                                        |                                        |
| No use                        | 1                                  |                                        | 1                                    |                                        |
| Antiplatelet only             | 0.97 (0.75–1.25)                   | 0.827                                  | 1.36 (0.67–2.76)                   | 0.394                                  |
| Warfarin only                 | 0.48 (0.22–1.02)                   | 0.058                                  | 2.23 (0.81–6.18)                   | 0.122                                  |
| Both                          | 0.39 (0.12–1.23)                   | 0.107                                  | 2.05 (0.57–7.38)                   | 0.271                                  |

AF = atrial fibrillation, AOR = adjusted odds ratio, CIED = cardiac implantable electronic device, CKD = chronic kidney disease, CRTD = cardiac resynchronized therapy-defibrillator, CRTP = cardiac resynchronized therapy-pacing, ICD = implantable cardioverter-defibrillator, PPM = permanent pacemaker.
study, the researchers proposed that temporary pacing leads were usually placed in emergencies and more leads in the right ventricle\textsuperscript{20} increased the perforation risk. In our clinical practice, we agree with that explanation. In terms of steroid use, although Mahapatra et al\textsuperscript{33} proposed that steroid use will make cardiac muscle weaker and atrophy as it does to skeletal muscle,\textsuperscript{33} there has been no published research to support this hypothesis, and thus requires further study.

Study Limitations

This retrospective analysis bears the inherent limitations of these types of studies. First, the information of the severity of the complications and procedures was not available, since the data were from an insurance system where diseases were classified according to ICD-9 codes and payment was made according to procedure type. Therefore, some complications may have been underestimated. Nonetheless, the complications requiring treatment were likely to be more important clinically than those without therapy. Second, information for some potential risks, including preoperative infections and procedure type (ie, cut-down vs puncture method) were not available in the analysis. However, the data were from the national insurance system that covers nearly every citizen in a country that may reduce systematic bias caused by a single operator or center and uncover factors that may not be readily found in studies of single clinics or with a small sample size. Therefore, such large number of patients and the complete follow-up should counterbalance the inherent study weaknesses.

CONCLUSION

In the CIED related infection, high-volume center can lower it and clinicians should pay more attention to young male patients and those who undergo device replacements. Preprocedure antibiotics remain important and cephalosporins should be considered a priority, especially in CIED replacement patients. As for heart perforation, temporary pacing should be avoided whenever possible after taking into account patient stability and timing to permanent pacing device. Careful attention should be paid when patients on steroids receive CIED implantations, due to the higher risk of heart perforation and it is recommended that steroids be discontinued if possible. Clinicians also should pay more attention to COPD patients and CRT patients in order to prevent pneumothorax.

REFERENCES

1. Vardas PE, Auricchio A, Blanc J, et al. Guidelines for cardiac pacing and cardiac resynchronization therapy: The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Eur Heart J. 2007;28:2256–2295.

2. Abikhzer G, Turpin S, Bigras JL. Infected pacemaker causing septic lung emboli detected on FDG PET/CT. J Nucl Cardiol. 2010;17:514–515.

3. Dickstein K, Vardas PE, Auricchio A, et al. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J. 2010;31:2677–2687.

4. Mond HG, Irwin M, Ector H, et al. The world survey of cardiac pacing and cardioverter-defibrillators: calendar Year 2005 an International Cardiac Pacing and Electrophysiology Society (ICPES) project. PACE. 2008;31:1202–1212.

5. Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009: a World Society of Arrhythmia’s project. PACE. 2011;34:1013–1027.

6. Cabell CH, Heidenreich PA, Chu VH, et al. Increasing rates of cardiac device infections among Medicare beneficiaries: 1990–1999. Am Heart J. 2004;147:582–586.

7. Voigt A, Shalaby A, Saba S. Continued rise in rates of cardiovascular implantable electronic device infections in the United States: temporal trends and causative insights. PACE. 2010;33:414–419.

8. Sohail MR, Henriksson CA, Braid-Forbes MJ, et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med. 2011;171:1821–1828.

9. Tompkins C, McLean R, Cheng A, et al. End-stage renal disease predicts complications in pacemaker and ICD implants. J Cardiovasc Electrophysiol. 2011;22:1099–1104.

10. Nery PB, Fernandes R, Nair GM, et al. Device-related infection among patients with pacemakers and implantable defibrillators: incidence, risk factors, and consequences. J Cardiovasc Electrophysiol. 2010;21:786–790.

11. Johansen JB, Jorgensen OD, Moller M, et al. Infection after pacemaker implantation: infection rates and risk factors associated with infection in a population-based cohort study of 46299 consecutive patients. Eur Heart J. 2011;32:991–998.

12. Remyer-Bouchard C, Da Costa A, Dauphinot V, et al. Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J. 2010;31:203–210.

13. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45:166–173.

14. Khug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation. 2007;116:1349–1355.

15. Raad D, Irani J, Akl EG, et al. Implantable electrophysiologic cardiac device infections: a risk factor analysis. J Eur Clin Microbiol Infect Dis. 2012;31:3015–3021.

16. Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic devices and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458–477.

17. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Pneumothorax in cardiac pacing: a population-based cohort study of 28,860 Danish patients. Europace. 2012;14:1132–1138.

18. Tobin K, Stewart J, Westveer D, et al. Acute complications of permanent pacemaker implantation: their financial implication and relation to volume and operator experience. Am J Cardiol. 2000;85:774–776.

19. Piekarsz J, Lelakowski J, Rydlewksa A, et al. Heart perforation in patients with permanent cardiac pacing—pilot personal observations. Arch Med Sci. 2012;8:70–74.

20. Mahapatra S, Bybee KA, Bunch TJ, et al. Incidence and predictors of cardiac perforation after permanent pacemaker placement. Heart Rhythm. 2005;2:907–911.

21. Wu C-Y. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection HBV nucleoside analogues, and HCC recurrence. JAMA. 2012;308:1906–1914.

22. Cheng CL, Kao YH, Lin SJ, et al. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Safety. 2011;20:236–242.
23. Gould PA, Gula LJ, Yee R, et al. Cardiovascular implantable electrophysiological device-related infections: a review. *Curr Opin Cardiol.* 2011;26:6–11.

24. Al-Khatib SM, Lucas FL, Jollis JG, et al. The relation between patients’ outcomes and the volume of cardioverter-defibrillator implantation procedures performed by physicians treating Medicare beneficiaries. *J Am Coll Cardiol.* 2005;46:1536–1540.

25. Freeman JV, Wang Y, Curtis JP, et al. The relation between hospital procedure volume and complications of cardioverter-defibrillator implantation from the implantable cardioverter-defibrillator registry. *J Am Coll Cardiol.* 2010;56:1133–1139.

26. Darouiche R, Mosier M, Voigt J. Antibiotics and antiseptics to prevent infection in cardiac rhythm management device implantation surgery. *PACE.* 2012;35:1348–1360.

27. Bloom H, Heeke B, Leon A, et al. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. *PACE.* 2006;29:142–145.

28. Dasgupta A, Montalvo J, Medendorp S, et al. Increased complication rates of cardiac rhythm management devices in ESRD patients. *Am J Kidney Dis.* 2007;49 (5):656–663.

29. Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. *Heart.* 2009;95:715–720.

30. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. *Eurpace.* 2010;12:103–108.

31. Khan MN, Joseph G, Khaykin Y, et al. Delayed lead perforation: a disturbing trend. *PACE.* 2005;28:251–253.

32. Hirschl DA, Jain VR, Spindola-Franco H, et al. Prevalence and characterization of asymptomatic pacemaker and ICD lead perforation on CT. *PACE.* 2007;30:28–32.

33. Twycross R. The risks and benefits of corticosteroids in advanced cancer. *Drug Saf.* 1994;11:163–178.